Vesynta is an investor-backed precision medicine company located in the London Cancer Hub, dedicated to developing clinical decision support software that personalizes dosing of critical therapies at the point of care. By providing clinicians with access to data-backed pharmacology models, Vesynta aims to reduce toxic side effects and enhance treatment efficacy, particularly for under-represented patient groups such as children, women, and individuals from diverse ethnic backgrounds. The company fosters a fast-paced, results-oriented, and mission-driven environment, focusing on delivering best-in-class actionable precision dosing insights to healthcare professionals through their innovative web, mobile, and Electronic Health Record-integrated applications.